6-K
ASTRAZENECA PLC (AZN)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of August 2025
Commission File Number: 001-11960
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
AstraZeneca PLC
INDEX TO EXHIBITS
1.
Holding(s) in Company
TR-1: Standard form for notification of major holdings
- Issuer Details
ISIN
| GB0009895292 |
|---|
Issuer Name
| ASTRAZENECA PLC |
|---|
UK or Non-UK Issuer
| UK |
|---|
- Reason for Notification
| An acquisition or disposal of voting rights |
|---|
- Details of person subject to the notification obligation
Name
| The Capital Group Companies, Inc. |
|---|
City of registered office (if applicable)
| Los Angeles |
|---|
Country of registered office (if applicable)
| USA |
|---|
- Details of the shareholder
Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above
City of registered office (if applicable)
Country of registered office (if applicable)
- Date on which the threshold was crossed or reached
| 22-Aug-2025 |
|---|
- Date on which Issuer notified
| 25-Aug-2025 |
|---|
- Total positions of person(s) subject to the notification obligation
| %<br>of voting rights attached to shares (total of 8.A) | %<br>of voting rights through financial instruments (total of 8.B 1 +<br>8.B 2) | Total<br>of both in % (8.A + 8.B) | Total<br>number of voting rights held in issuer | |
|---|---|---|---|---|
| Resulting situation<br>on the date on which threshold was crossed or reached | 5.009701 | 0.000000 | 5.009701 | 77684561 |
| Position of<br>previous notification (if applicable) | 4.997854 | 0.000000 | 4.997854 |
- Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
| Class/Type of shares ISIN code(if possible) | Number of direct voting rights (DTR5.1) | Number of indirect voting rights (DTR5.2.1) | % of direct voting rights (DTR5.1) | % of indirect voting rights (DTR5.2.1) |
|---|---|---|---|---|
| GB0009895292 Common<br>Stock | 62998778 | 4.062648 | ||
| US0463531089<br>Depository Receipt | 14685783 | 0.947053 | ||
| Sub<br>Total 8.A | 77684561 | 5.009701% |
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
| Type of financial instrument | Expiration date | Exercise/conversion period | Number of voting rights that may be acquired if the instrument is<br>exercised/converted | % of voting rights |
|---|---|---|---|---|
| Sub<br>Total 8.B1 |
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
| Type of financial instrument | Expiration date | Exercise/conversion period | Physical or cash settlement | Number of voting rights | % of voting rights |
|---|---|---|---|---|---|
| Sub<br>Total 8.B2 |
- Information in relation to the person subject to the notification obligation
| 2. Full chain of controlled undertakings through which the voting<br>rights and/or the financial instruments are effectively held<br>starting with the ultimate controlling natural person or legal<br>entities (please add additional rows as necessary) | ||||
|---|---|---|---|---|
| Ultimate controlling person | Name of controlled undertaking | % of voting rights if it equals or is higher than the notifiable<br>threshold | % of voting rights through financial instruments if it equals or is<br>higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable<br>threshold |
| --- | --- | --- | --- | --- |
| The<br>Capital Group Companies, Inc. | Capital<br>Research and Management Company | |||
| The<br>Capital Group Companies, Inc. | Capital<br>International, Inc. | |||
| The<br>Capital Group Companies, Inc. | Capital<br>Group Private Client Services, Inc. | |||
| The<br>Capital Group Companies, Inc. | Capital<br>International Sarl | |||
| The<br>Capital Group Companies, Inc. | Capital<br>International Limited |
- In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
- Additional Information
| The Capital Group Companies, Inc. ("CGC") is the parent company of<br>Capital Research and Management Company ("CRMC") and Capital Bank<br>& Trust Company ("CB&T"). CRMC is a U.S.-based investment<br>management company that serves as investment manager to the<br>American Funds family of mutual funds, other pooled investment<br>vehicles, as well as individual and institutional clients. CRMC and<br>its investment manager affiliates manage equity assets for various<br>investment companies through three divisions, Capital Research<br>Global Investors, Capital International Investors and Capital World<br>Investors. CRMC is the parent company of Capital Group<br>International, Inc. ("CGII"), which in turn is the parent company<br>of six investment management companies ("CGII management<br>companies"): Capital International, Inc., Capital International<br>Limited, Capital International Sàrl, Capital International<br>K.K., Capital Group Private Client Services Inc, and Capital Group<br>Investment Management Private Limited. CGII management companies<br>primarily serve as investment managers to institutional and high<br>net worth clients. CB&T is a U.S.-based registered investment<br>adviser and an affiliated federally chartered bank.Neither CGC nor<br>any of its affiliates own shares of the Issuer for its own account.<br>Rather, the shares reported on this Notification are owned by<br>accounts under the discretionary investment management of one or<br>more of the investment management companies described<br>above. |
|---|
- Date of Completion
| 25-Aug-2025 |
|---|
- Place Of Completion
| Los Angeles |
|---|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AstraZeneca<br>PLC |
|---|
Date: 26 August 2025
| By: /s/<br>Matthew Bowden |
|---|
| Name:<br>Matthew Bowden |
| Title:<br>Company Secretary |